This guideline sets out an antimicrobial prescribing strategy for acute pyelonephritis (upper urinary tract infection) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
This guideline sets out an antimicrobial prescribing strategy for acute prostatitis. It aims to optimise antibiotic use and reduce antibiotic resistance.
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)
Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura (chronic ITP)
Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults
Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults
Evidence-based recommendations on iFuse titanium implant joint fusion system for treating chronic sacroiliac (SI) joint pain (lower back pain)
Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta
Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL)
Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy (nerve damage) by detecting inadequate sweat production
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma (cHL) in adults
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults
Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over
Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults
Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults
Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for differentiated thyroid cancer in adults who have had radioactive iodine
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis (MS) in adults
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Evidence-based recommendations on cenegermin (Oxervate) for treating neurotrophic keratitis in adults
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults
Evidence-based recommendations on biomarker tests (Actim Partus, PartoSure, Rapid fFN 10Q Cassette) to diagnose preterm labour in women with intact membranes
Evidence-based recommendations on niraparib (Zejula) for the possible treatment of ovarian, fallopian tube or peritoneal cancer in adults
Evidence-based recommendations on nivolumab (Opdivo) for locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults
Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) to treat multiple sclerosis in adults
Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory CD30-positive Hodgkin lymphoma in adults
Evidence-based recommendations on arsenic trioxide (Trisenox)for treating acute promyelocytic leukaemia (APML) in adults
Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults
Evidence-based recommendations on on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia (AML) in adults
Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults
Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer (NSCLC) after chemotherapy in adults
Evidence-based recommendations on DYSIS colposcope with DYSISmap and ZedScan I for assessing suspected cervical abnormalities in people having colposcopy
Evidence-based recommendations on pembrolizumab (Keytruda) for locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults
Evidence-based recommendations on avelumab (Bavencio) for treating metastatic (secondary) Merkel cell carcinoma (skin cancer) in adults
Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course
This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.
Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer (MTC) in adults
Evidence-based recommendations on Thopaz+ for people who need chest drainage after a pulmonary resection or because of a collapsed lung
Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults
This guidance has been updated and replaced by NICE technology appraisal guidance 555.
Evidence-based recommendations on tivozanib (Fotivda) for previously untreated advanced renal cell carcinoma (RCC/kidney cancer) in adults
Evidence-based recommendations on daratumumab (Darzalex) for relapsed or refractory multiple myeloma in adults
Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive, locally recurrent or metastatic (secondary) breast cancer in adults
Evidence-based recommendations on autologous chondrocyte implantation (ACI) using chondrosphere (Spherox) for symptomatic articular knee cartilage defects